GanLee’s GZC8072 Wins NMPA IND Approval for Once‑Weekly Oral Type 2 Diabetes Candidate

Gan & Lee Pharmaceuticals (SHA: 603087) announced that its drug candidate GZC8072 has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for the treatment of type 2 diabetes. The clearance marks a key regulatory step for the company’s next-generation, ultra-long-acting oral weekly peptide, a molecule class for which no approved therapy currently exists worldwide.

Regulatory Milestone

Drug Profile & Mechanism of Action

• Molecule: GZC8072, a next-generation biased, ultra-long-acting oral weekly peptide independently developed by Gan & Lee Pharmaceuticals
• Therapeutic Class: Oral GLP-1-class peptide candidate for type 2 diabetes, designed to support a once-weekly oral dosing regimen
• Innovation: Biased agonism combined with extended half-life engineering to enhance potency and durability of effect
• Platform Technology: Built on the company’s proprietary NovaPeptide and SupOraTide platforms
• Bioavailability: Significantly improved oral bioavailability versus conventional peptide formulations — a core differentiator for oral weekly dosing
• IP Position: Independently developed molecule leveraging in-house platform technologies

Development Status & Clinical Outlook

• GZC8072 has cleared the IND stage; clinical trials are the next phase of development
• As of the announcement’s disclosure date, no oral weekly GLP-1 tablet has been approved globally for type 2 diabetes, placing the candidate in an emerging and highly competitive category
• The once-weekly oral regimen, if validated in clinical studies, would offer a meaningful convenience advantage over daily oral and injectable GLP-1 therapies

Market Impact & Outlook

• First-mover opportunity: The global absence of an approved oral weekly GLP-1 tablet for type 2 diabetes creates a significant white space that GZC8072 is positioned to address
• Platform validation: IND approval provides early regulatory validation of Gan & Lee’s NovaPeptide and SupOraTide discovery platforms
• Competitive positioning: Ultra-long-acting, once-weekly oral dosing could differentiate the candidate against established daily oral and weekly injectable GLP-1 therapies on convenience and adherence
• Pipeline momentum: Strengthens Gan & Lee Pharmaceuticals’ transition beyond its insulin franchise into next-generation incretin-based therapies

Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug development, regulatory approval and market potential are forward-looking and subject to risks and uncertainties, including clinical outcomes, regulatory decisions and competitive developments. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech